3-oxoquinuclidine oxime | 78961-48-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 奎宁环
• 英文名称: 3-oxoquinuclidine oxime
• 英文别名: 3-hydroxyiminoquinuclidine；3-Chinuclidonoxim；1-Azabicyclo[2.2.2]octan-3-one oxime；(NE)-N-(1-azabicyclo[2.2.2]octan-3-ylidene)hydroxylamine
• CAS: 78961-48-5
• 化学式: C₇H₁₂N₂O
• 分子量: 140.185
• InChiKey: QSXHBTDHLNHMLV-FPLPWBNLSA-N

物化性质

• 沸点：
  261.0±23.0 °C(Predicted)
• 密度：
  1.39±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  35.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-oxoquinuclidine oxime 生成 (Z)-1-aza-bicyclo[2.2.2]octan-3-one oxime
  参考文献：
  名称：

  FILIPENKO T. YA.; GORBYLEVA O. I.; TURCHIN K. F.; ANISIMOVA O. S.; PERESL+, XIMIYA GETEROTSIKL. SOEDIN., 1981, HO 5, 666-674

  摘要：

  DOI：
• 作为产物：
  描述：

  3-奎宁环酮 在 盐酸羟胺 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 1.0h， 生成 3-oxoquinuclidine oxime
  参考文献：
  名称：

  基于奎宁环的新型强效抗菌剂

  摘要：

  开发新的抗生素目前非常重要，因为抗生素耐药性是当今全球健康的最大问题之一。在寻找一类新的潜在抗菌剂的过程中，基于奎宁环核和肟官能团设计并合成了十种新化合物。针对一组代表性的革兰氏阳性菌和革兰氏阴性菌评估了抗微生物活性。所有化合物均显示出对测试微生物的有效活性，最小抑菌浓度 (MIC) 值范围为 0.25 至 256.00 μg/mL。在测试的化合物中，两种季化合物，对-N-氯苄基和间-N-溴苄基奎宁环肟，对革兰氏阳性和革兰氏阴性细菌菌株显示出最有效和广谱的活性（MIC 值从 0.25 到 4.00 μg/mL），对重要的多重耐药革兰氏阴性病原体铜绿假单胞菌的值最低。就肺炎克雷伯菌而言，这些化合物的活性分别比庆大霉素好 256 倍和 16 倍。MTT 分析表明化合物对人类细胞系无毒。采用多路分析分别对量子化学数据和生物活性数据进行降维，得到回归模型和增强生物活性所需的参数。这些化合物的活性分别比庆大霉素好

  DOI：

  10.3390/molecules24142675

文献信息

• Synthesis and evaluation of conformationally restricted N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)ethylamines at .sigma. receptors. 2. Piperazines, bicyclic amines, bridged bicyclic amines, and miscellaneous compounds
  作者：Brian R. de Costa、Xiaoshu He、Joannes T. M. Linders、Celia Dominguez、Zi Qiang Gu、Wanda Williams、Wayne Bowen

  DOI：10.1021/jm00068a007

  日期：1993.8

  4-dichlorophenyl)ethyl]-1,4-diazabicyclo[3.2.2]nonane (16)] show very weak sigma interaction. Comparison of the binding data of different N-substituted homologues of 1 with those of the 1-[2-(3,4-dichlorophenyl)ethyl]-4-alkylpiperazines suggests that the two nitrogen atoms of 1 are working in opposition to one another in terms of their sensitivity to steric bulk. The high binding affinity of the 1,4-diazabicyclo[4

  作为我们先前研究（J. Med。Chem。1992，35，4334-4343）的继续，我们构象限制了sigma-受体配体2-（1-吡咯烷基）-N- [2-（3,4-二氯苯基）乙基] -N-甲基乙胺（1）掺入一系列同源的哌嗪3-9和均哌嗪10和11中，二氮杂双环壬烷和癸烷，桥头双环辛烷和壬烷以及其他其他化合物。使用[3H]（+）-喷他佐辛在豚鼠脑膜sigma 1位点获得sigma-受体结合亲和力。研究表明，在哌嗪中发现的氮孤对取向提供最强的结合相互作用。其他氮孤对取向或代表1 [不可能的交错构象的化合物，如4- [2-（3,4-二氯苯基）乙基] -1,4-二氮杂双环[3.2]。2] nonane（16）]显示非常弱的sigma相互作用。比较1的不同N-取代同系物与1- [2-（3,4-二氯苯基）乙基] -4-烷基哌嗪的结合数据表明，1的两个氮原子彼此相反。就其对空间体积的敏感性而言。1,4-二氮杂双环[4
• [EN] NOVEL DIBENZOFURANYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL USE<br/>[FR] NOUVEAUX DÉRIVÉS DE DIBENZOFURANYL-OXADIAZOLYL-DIAZABICYCLONONANE, ET UTILISATION MÉDICALE DE CEUX-CI
  申请人：NEUROSEARCH AS

  公开号：WO2010086279A1

  公开（公告）日：2010-08-05

  This invention relates to novel dibenzofuranyl-oxadiazolyl-diazabicyclononane derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  这项发明涉及新型的二苯并呋喃基-噁二唑基-二氮杂双环壬烷衍生物及其在制备药物组合物中的应用。该发明的化合物被发现是胆碱能受体的胆碱能配体，同时也是单胺受体和转运体的调节剂。由于它们的药理特性，该发明的化合物可能对治疗与中枢神经系统（CNS）的胆碱能系统、外周神经系统（PNS）、平滑肌收缩、内分泌疾病、神经退行性疾病、炎症、疼痛以及由于滥用化学物质终止而引起的戒断症状等各种疾病或紊乱具有用处。
• [EN] DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS<br/>[FR] DERIVES D'ARYLE DIAZABICYCLIQUES CONSTITUANT DES MODULATEURS DES RECEPTEURS CHOLINERGIQUES
  申请人：NEUROSEARCH AS

  公开号：WO2005074940A1

  公开（公告）日：2005-08-18

  This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemicals substances.

  这项发明涉及新型的二氮杂双环芳基衍生物，发现它们在尼古丁乙酰胆碱受体上是胆碱能配体，并且调节单胺受体和转运体。由于它们的药理特性，本发明的化合物可能对治疗与中枢神经系统（CNS）的胆碱能系统、外周神经系统（PNS）、平滑肌收缩相关的疾病或障碍、内分泌疾病或障碍、神经退行性疾病或障碍、炎症相关的疾病或障碍、疼痛以及由于滥用化学物质而导致的戒断症状等多种疾病或障碍具有用处。
• [EN] NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL HETEROARYL DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS<br/>[FR] NOUVEAUX DÉRIVÉS DE 1,4-DIAZA-BICYCLO[3.2.2]NONYL HÉTÉROARYLE UTILES EN TANT QUE LIGANDS DES RÉCEPTEURS NICOTINIQUES DE L'ACÉTYLCHOLINE
  申请人：NEUROSEARCH AS

  公开号：WO2009024517A1

  公开（公告）日：2009-02-26

  This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl heteroaryl derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation,pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  这项发明涉及新颖的1,4-二氮杂双环[3.2.2]壬基杂环芳烃衍生物及其在制备药物组合物中的应用。该发明的化合物被发现是胆碱能配体，作用于尼古丁乙酰胆碱受体。由于其药理特性，该发明的化合物可能有助于治疗与中枢神经系统（CNS）的胆碱系统相关的疾病或紊乱，外周神经系统（PNS），与平滑肌收缩相关的疾病或紊乱，内分泌疾病或紊乱，与神经退行性相关的疾病或紊乱，与炎症、疼痛以及由于滥用化学物质终止而引起的戒断症状相关的疾病或紊乱。
• [EN] NOVEL DIAZA-BICYCLONONYL-PYRIMIDINYL DERIVATIVES AND THEIR MEDICAL USE<br/>[FR] NOUVEAUX DÉRIVÉS DE DIAZA-BICYCLONONYL-PYRIMIDINYLE ET LEURS APPLICATIONS MÉDICALES
  申请人：NEUROSEARCH AS

  公开号：WO2010084121A1

  公开（公告）日：2010-07-29

  This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl pyhmidine derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  这项发明涉及新型的1,4-二氮杂双环[3.2.2]壬基吡啶衍生物及其在制备药物组合物中的应用。该发明的化合物被发现是胆碱能受体的配体，在尼古丁乙酰胆碱受体上起调节作用，并且在单胺受体和转运体上也有调节作用。由于它们的药理特性，这些发明的化合物可能对治疗与中枢神经系统（CNS）的胆碱能系统、外周神经系统（PNS）、平滑肌收缩相关的疾病或障碍、内分泌疾病或障碍、神经退行性疾病或障碍、炎症相关的疾病或障碍、疼痛以及因滥用化学物质而导致的戒断症状等多种疾病或障碍具有用处。